Collegium Pharmaceutical, Inc. (COLL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.56%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 5.56% | Share-based compensation / revenue. Period ending 2026-06-30. $44.93M ÷ $808.21M × 100 ≈ 5.56% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 808.21M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 44.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 157.44M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $808.21M | $44.93M | $157.44M | (m) | (m) | 5.56% | (m) | (m) |
| 2026-03-31 | (m) | $796.33M | $41.26M | $188.84M | (m) | (m) | 5.18% | (m) | (m) |
| 2025-12-31 | (m) | $780.57M | $41.91M | $179.64M | (m) | (m) | 5.37% | (m) | (m) |
| 2025-09-30 | (m) | $757.07M | $39.75M | $156.99M | (m) | (m) | 5.25% | (m) | (m) |
| 2025-06-30 | (m) | $707.01M | $37.26M | $129.74M | (m) | (m) | 5.27% | (m) | (m) |
| 2025-03-31 | (m) | $664.28M | $36.45M | $142.11M | (m) | (m) | 5.49% | (m) | (m) |
| 2024-12-31 | $0.00 | $631.45M | $32.40M | $169.90M | (m) | 0.00% | 5.13% | (m) | (m) |
| 2024-09-30 | (m) | $599.25M | $31.81M | $193.47M | (m) | (m) | 5.31% | (m) | (m) |
| 2024-06-30 | (m) | $576.65M | $31.52M | $203.65M | (m) | (m) | 5.47% | (m) | (m) |
| 2024-03-31 | (m) | $566.92M | $28.58M | $191.81M | $79.25M | (m) | 5.04% | 2.42× | Reported |
| 2023-12-31 | $0.00 | $566.77M | $27.14M | $166.96M | $83.34M | 0.00% | 4.79% | 2.00× | Reported |
| 2023-09-30 | (m) | $546.64M | $25.80M | $117.03M | $84.63M | (m) | 4.72% | 1.38× | Reported |
| 2023-06-30 | (m) | $536.95M | $24.15M | $92.48M | $82.91M | (m) | 4.50% | 1.12× | Reported |
| 2023-03-31 | (m) | $524.95M | $22.77M | $67.96M | $78.81M | (m) | 4.34% | 0.86× | Reported |
| 2022-12-31 | $3.98M | $463.93M | $22.87M | $33.32M | $63.21M | 0.86% | 4.93% | 0.53× | Reported |
| 2022-09-30 | $5.59M | $361.68M | $22.12M | $-12.56M | $47.40M | 1.55% | 6.11% | -0.27× | Reported |
| 2022-06-30 | $7.04M | $313.50M | $22.69M | $-18.88M | $33.46M | 2.25% | 7.24% | -0.56× | Reported |
| 2022-03-31 | $10.50M | $272.90M | $23.51M | $-13.58M | $21.12M | 3.85% | 8.62% | -0.64× | Reported |
| 2021-12-31 | $9.45M | $276.87M | $24.25M | $17.63M | $21.01M | 3.41% | 8.76% | 0.84× | Reported |
| 2021-09-30 | $10.31M | $325.78M | $25.55M | $66.75M | $23.99M | 3.17% | 7.84% | 2.78× | Reported |
| 2021-06-30 | $11.01M | $326.11M | $24.77M | $72.22M | $26.94M | 3.37% | 7.60% | 2.68× | Reported |
| 2021-03-31 | $10.04M | $321.23M | $23.84M | $72.36M | $29.78M | 3.12% | 7.42% | 2.43× | Reported |
| 2020-12-31 | $9.77M | $310.02M | $21.91M | $56.23M | $28.88M | 3.15% | 7.07% | 1.95× | Reported |
| 2020-09-30 | $9.70M | $307.95M | $19.67M | $38.86M | $21.36M | 3.15% | 6.39% | 1.82× | Reported |
| 2020-06-30 | $10.05M | $301.71M | $18.64M | $12.86M | $13.52M | 3.33% | 6.18% | 0.95× | Reported |
| 2020-03-31 | $10.01M | $298.70M | $17.22M | $-8.70M | $5.50M | 3.35% | 5.76% | -1.58× | Reported |
| 2019-12-31 | $10.34M | $296.70M | $16.53M | $-23.75M | $909.00K | 3.48% | 5.57% | -26.13× | Reported |
| 2019-09-30 | $10.19M | $295.93M | $16.16M | $-10.37M | $3.10M | 3.44% | 5.46% | -3.34× | Reported |
| 2019-06-30 | $9.61M | $293.16M | $15.95M | $-15.19M | $8.74M | 3.28% | 5.44% | -1.74× | Reported |
| 2019-03-31 | $9.38M | $291.18M | $15.31M | $-17.47M | $14.66M | 3.22% | 5.26% | -1.19× | Reported |
| 2018-12-31 | $8.66M | $280.41M | $13.78M | $-20.68M | $20.13M | 3.09% | 4.91% | -1.03× | Reported |
| 2018-09-30 | $8.61M | (m) | $12.26M | $-49.27M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $8.77M | (m) | $10.43M | $-51.51M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $8.71M | (m) | $8.85M | $-65.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $8.57M | (m) | $7.95M | $-75.45M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $9.71M | (m) | $7.52M | $-85.44M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $10.89M | (m) | $7.06M | $-98.45M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $13.02M | (m) | $6.51M | $-101.67M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $14.95M | (m) | $5.79M | $-94.08M | $94.00K | (m) | (m) | -1000.87× | Reported |
| 2016-09-30 | $13.15M | (m) | $5.13M | $-75.94M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $13.25M | (m) | $3.99M | $-58.76M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $10.59M | (m) | $3.20M | $-38.86M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $7.97M | (m) | $2.21M | $-26.91M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $14.96M | (m) | $22.00K | $-17.66M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $14.16M | (m) | $62.00K | $-16.04M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |